Stock image for illustration purposes only - book cover, edition or condition may vary.
Modern Strategy for Preclinical Pharmaceutical R and D
David Cavalla
€ 285.58
FREE Delivery in Ireland
Description for Modern Strategy for Preclinical Pharmaceutical R and D
Hardcover. The emphasis on cost-effectiveness within the pharmaceutical industry has caused it to outsource some development work. This text addresses the advantages and disadvantages of collaborations between industrial research and development divisions and contract research organizations and universities. Num Pages: 228 pages, Ill. BIC Classification: KNDP; MBGR; TDCW. Category: (P) Professional & Vocational; (UP) Postgraduate, Research & Scholarly. Dimension: 242 x 165 x 18. Weight in Grams: 488.
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, ... Read more
The twentieth century has been a great success for modern medicine, and has resulted in the generation of a plethora of drugs to treat most common illnesses. However, in the light of increasing regulatory demands, spiralling costs and diminishing commercial returns, the question of how, when, where and whether to conduct pharmaceutical R&D has profound implications, and not just for those within the pharmaceutical industry. In response to these and other dilemmas, the authors define the processes involved in drug research, and examine the advantages and disadvantages of collaborative methods of drug research, and examine the roles that academia, CROs, ... Read more
Product Details
Format
Hardback
Publication date
1997
Publisher
John Wiley and Sons Ltd United Kingdom
Number of pages
228
Condition
New
Number of Pages
228
Place of Publication
New York, United States
ISBN
9780471971177
SKU
V9780471971177
Shipping Time
Usually ships in 7 to 11 working days
Ref
99-50
About David Cavalla
David Cavalla is an expert on secondary uses for existing drugs, or drug repurposing. He currrently operates through his consultancy, Numedicus Ltd, having worked in drug repurposing for 15 years. Previously he was CEO of Arachnova, and prior to that held various senior positions in pharmaceutical drug discovery at GSK and Napp Research Centre. He has written widely on drug ... Read more
Reviews for Modern Strategy for Preclinical Pharmaceutical R and D